Literature DB >> 15542396

Expression and functional characterization of human mutant sulfamidase in insect cells.

Magda Montfort1, Elena Garrido, John J Hopwood, Daniel Grinberg, Amparo Chabás, Lluïsa Vilageliu.   

Abstract

Mucopolysaccharidosis IIIA (MPS IIIA; Sanfilippo syndrome) is an autosomal recessive lysosomal disorder caused by the deficiency of sulfamidase (EC 3.10.1.1), required for the degradation of the mucopolysaccharide heparan sulfate. The molecular defects of 26 unrelated Spanish MPS IIIA patients were recently reported by our group. Here we describe the heterologous expression, using a baculovirus system, of the cDNAs corresponding to eight out of the 14 mutant alleles present in this patient group and the characterization of the corresponding mutant enzymes. In particular, we expressed the following alleles: p.S66W, p.R74H, p.Q85R, p.R206P, p.L386R, p.R433W, p.R433Q, and c.1079delC (previously named as c.1091delC), and the two variants of the polymorphism p.R456H. The expression of the mutant alleles and the characterization of the corresponding enzymes revealed that their activity was severely compromised. Only mutations p.S66W and p.R206P retained low levels of residual activity. However, Western blot analysis showed in all cases the presence of the expected two forms of the sulfamidase, the precursor and the mature proteins, indicating a normal processing of the mutant enzyme.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542396     DOI: 10.1016/j.ymgme.2004.07.001

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  2 in total

1.  Natural history of Sanfilippo syndrome in Spain.

Authors:  Verónica Delgadillo; Maria del Mar O'Callaghan; Laura Gort; Maria Josep Coll; Mercedes Pineda
Journal:  Orphanet J Rare Dis       Date:  2013-12-06       Impact factor: 4.123

2.  Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells.

Authors:  Ruben J Boado; Jeff Zhiqiang Lu; Eric Ka-Wai Hui; William M Pardridge
Journal:  Mol Pharm       Date:  2014-06-26       Impact factor: 4.939

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.